The Cheapest Way to Get a GLP-1 in 2026
List prices for Ozempic, Wegovy, Mounjaro and Zepbound run past $1,000 a month — but almost nobody pays that. Here are the actual cheapest routes for semaglutide and tirzepatide, ranked by what you’d really pay, with the trade-offs spelled out.
The short answer
The cheapest GLP-1 for most uninsured people is compounded semaglutide or tirzepatide via telehealth (from about $69/mo), though compounded drugs are not FDA-reviewed. The cheapest brand-name route is a manufacturer cash-pay vial — Zepbound via LillyDirect from ~~$299/mo, Wegovy via NovoCare from ~$349/mo. With commercial insurance, a savings card can cut your copay to near $0.
Every cheapest route, compared
| Route | Typical monthly cost | Who it’s for | Catch |
|---|---|---|---|
| Compounded via telehealth | from ~$69/mo | Cash-pay; no insurance needed | Compounded drugs are NOT FDA-reviewed for safety, quality or effectiveness |
| Brand cash-pay vials (LillyDirect / NovoCare) | ~$299–$699/mo | Uninsured or no GLP-1 coverage | Lower doses only; self-pay direct from the manufacturer |
| Manufacturer savings card | As low as $0–$25/mo copay | Commercial insurance only | Not valid with Medicare/Medicaid; coverage must already exist |
| Insurance + prior authorization | Plan copay (varies) | Covered plans | Many plans exclude weight-loss use; appeals often needed |
| Pharmacy discount card | Varies; rarely beats cash-pay for brand GLP-1s | Anyone, no insurance | Cannot be combined with insurance |
Prices are estimates as of June 2026, set by manufacturers/providers and subject to change — confirm current pricing before buying. GLP1Zoom is not a pharmacy.
Cheapest semaglutide
Semaglutide is sold as Wegovy (weight loss), Ozempic and Rybelsus (diabetes). The cheapest cash route is compounded semaglutide via telehealth (from about $69/mo); the cheapest brand route is NovoCare cash-pay Wegovy vials (~$349/mo). With commercial insurance, the Wegovy savings card can reach ~$0 copay.
Cheapest tirzepatide
Tirzepatide is sold as Zepbound (weight loss) and Mounjaro (diabetes). The cheapest cash route is compounded tirzepatide via telehealth (from about $69/mo); the cheapest brand route is LillyDirect cash-pay Zepbound vials (from ~~$299/mo) — currently the lowest brand entry price of any GLP-1.
Compare the lowest cash-pay GLP-1 providers
SponsoredRanked by our editorial score. Visit a partner to check current cash-pay pricing and eligibility — we compare providers, we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
Dig into the numbers
Cheapest isn’t always best
Compounded GLP-1s are the lowest-cost option but are not FDA-reviewed for safety, quality or effectiveness, and access has narrowed since the official shortages ended. All GLP-1s are prescription-only and carry a boxed warning for thyroid C-cell tumors. This page is educational, not medical advice — discuss the right option with a licensed clinician. GLP1Zoom is an independent comparison site, not a pharmacy.
Cheapest GLP-1 without insurance
With no coverage, manufacturer savings cards are off the table — they require commercial insurance — so the real choice is between compounded products and manufacturer self-pay. Ordered cheapest first, with what each one actually costs you.
| Route | Monthly cost | Best for | The catch |
|---|---|---|---|
| Compounded semaglutide via telehealth | $69–$300/mo | Lowest monthly cost of any route | Not FDA-approved. The shortage that justified mass compounding ended in February 2025, and most of it ships as a vial and syringe rather than a metered pen. |
| Compounded tirzepatide via telehealth | $99–$450/mo | Lowest cost for the more effective molecule | Not FDA-approved; tirzepatide’s shortage ended December 2024. Same vial-and-syringe dosing caveat. |
| Oral semaglutide, manufacturer self-pay | from $149/mo | Cheapest FDA-approved route, and no injection | Starting-dose pricing; a tablet taken daily rather than a weekly shot. |
| Zepbound self-pay (Lilly) | $299/mo (2.5 mg) | Cheapest brand tirzepatide entry point | 2.5 mg is a starting dose nobody stays on. Maintenance is $449/mo (7.5 mg and up) only if you refill within 45 days — otherwise $699/mo (10, 12.5, 15 mg). |
| Wegovy / Ozempic self-pay (NovoCare) | ~$349/mo for maintenance doses | FDA-approved brand, direct from the manufacturer | The advertised $199 covers the first two fills only — budget the maintenance figure. |
Two costs the monthly price hides. Telehealth providers may charge a separate consultation fee on top of the medication — a low monthly price with a high consult fee can cost more in month one than the reverse. And any discounted maintenance price that depends on a refill window becomes a calendar commitment, not just a price. The provider ranking now sorts by first-month total including the consultation fee for exactly this reason.
Common questions about Cheapest GLP-1
What is the cheapest GLP-1 medication?
For most uninsured people in 2026 the cheapest route is compounded semaglutide or tirzepatide through a telehealth provider, starting around $69 a month. The cheapest brand-name option is a manufacturer cash-pay vial program — Eli Lilly’s LillyDirect (Zepbound) from about ~$299/month and Novo Nordisk’s NovoCare (Wegovy) from about $349/month. If you have commercial insurance, a manufacturer savings card can drop your copay close to $0. Compounded drugs are not FDA-reviewed, so weigh cost against that trade-off and talk to a licensed provider.
What is the cheapest way to get Wegovy or Ozempic?
Without insurance, Novo Nordisk’s NovoCare cash-pay program offers semaglutide vials from around $349/month — usually cheaper than a pharmacy discount card for brand Wegovy. With commercial insurance, the Wegovy savings card can bring your copay to as low as $0–$25. Ozempic is a diabetes drug, so coverage and savings cards apply to a diabetes diagnosis. Confirm current pricing with the manufacturer before buying.
Is compounded semaglutide or tirzepatide really cheaper?
Yes — compounded versions through telehealth are usually the lowest cash price (from about $69/month). But compounded drugs are prepared by pharmacies and are not reviewed by the FDA for safety, quality or effectiveness, and availability has tightened as the official shortages ended. They are a lower-cost option, not an FDA-approved equivalent. See our compounded semaglutide and tirzepatide explainers for the current rules.
What is the cheapest GLP-1 without insurance?
Ranked cheapest-first for cash-pay: (1) compounded semaglutide/tirzepatide via telehealth from ~$69/mo; (2) brand cash-pay vials (LillyDirect Zepbound ~$349, NovoCare Wegovy ~$349); (3) pharmacy discount cards, which rarely beat the manufacturer cash programs for brand GLP-1s. Manufacturer savings cards do not help the uninsured because they require commercial insurance. Prices change often — verify before purchasing.
Is tirzepatide or semaglutide cheaper?
They are close. Brand cash-pay vials make tirzepatide (Zepbound via LillyDirect, from ~~$299/mo) slightly cheaper than semaglutide (Wegovy via NovoCare, from ~$349/mo) at the entry doses as of June 2026. Compounded versions of both run a similar from about $69/month. Tirzepatide also produced more weight loss in head-to-head trials — see our semaglutide vs tirzepatide comparison.
How we sourced these prices
Cash-pay figures reflect the publicly posted LillyDirect (Zepbound) and NovoCare (Wegovy) self-pay vial programs and typical telehealth compounded pricing as of June 2026; savings-card terms come from each manufacturer’s program. All prices change without notice — always confirm the current price with the manufacturer or provider before purchasing. Last reviewed 2026-06-26.
Compare GLP-1 costs
References(7)
Our sourcing standards →- CMS — Medicare GLP-1 coverage (Part D $50/mo pilot, from July 1, 2026) — Centers for Medicare & Medicaid Services (2026)
- Novo Nordisk plans to cut Wegovy list price to ~$675 in 2027; discounts at $149/mo now — Reuters (2026)
- FDA sends 25 warning letters to telehealth companies over compounded GLP-1 claims — Reuters (2026)
- FDA clarifies policies for compounders as national GLP-1 supply stabilizesFDA — U.S. Food and Drug Administration (2026)